腺病毒|阿斯利康新冠疫苗获英国紧急使用授权,调整接种方案有望提高保护效力( 二 )


其它可能影响疫苗效力的因素包括不同接种程序对T细胞免疫应答,以及免疫记忆生成的影响 。
我们期待进一步研究不但能够找到提高基于腺病毒载体的新冠疫苗保护效力的方法,而且帮助优化腺病毒载体疫苗的设计和开发 。
注:本文旨在介绍医药健康研究,不是治疗方案推荐 。如需获得治疗方案指导,请前往正规医院就诊 。
【腺病毒|阿斯利康新冠疫苗获英国紧急使用授权,调整接种方案有望提高保护效力】参考资料:
[1] Oxford University/AstraZeneca vaccine authorised by UK medicines regulator. Retrieved December 30, 2020, from https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator
[2] AZD1222 Oxford Phase III trials interim analysis results published in The Lancet. Retrieved December 30, 2020, from https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222-oxford-phase-iii-trials-interim-analysis-results-published-in-the-lancet.html
[3] AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK. Retrieved December 30, 2020, from https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html
[4] Voysey et al, (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, DOI:https://doi.org/10.1016/S0140-6736(20)32661-1.
[5] Information_for_UK_healthcare_professionals_on_COVID-19_Vaccine_AstraZeneca. Retrieved December 30, 2020, from https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948334/Information_for_UK_healthcare_professionals_on_COVID-19_Vaccine_AstraZeneca.pdf
[6] Pascal Soriot interview: ‘Astra Zeneca has winning formula to beat Covid-19. Retrieved December 30, 2020, from https://www.thetimes.co.uk/article/pascal-soriot-interview-astra-zeneca-has-winning-formula-to-beat-covid-19-httk3wzkm
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台 。

推荐阅读